An open-label study of the efficacy, safety and tolerability of oral BTD-001 in adults with idiopathic hypersomnia or narcolepsy type 2

Introduction: Recent research suggests that an endogenous agent in the central nervous system of idiopathic hypersomnia (IH) and narcolepsy type-2 (Na-2) patients acts as a GABA agonist and may be a key driver of debilitation. We assessed the efficacy and safety of BTD-001, a GABAA receptor (GABAAR) antagonist in IH and Na-2 in a pilot clinical study.

from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2FKKzFQ